News | August 20, 2009

McKesson's Molecular Diagnostics Criteria Surpasses 380 Tests

August 20, 2009 - McKesson updated its InterQual Molecular Diagnostics Criteria to cover more than 380 tests, including a new category of pharmacogenomic tests that determine if an individual will be responsive to a drug based on genetic makeup.

As the first vendor to provide a comprehensive set of evidence-based criteria to support decision-making for molecular diagnostic tests, McKesson is now extending the power of this offering to help healthcare payors and providers to ensure patients receive the most appropriate medical care and better manage medical spend.
The added content in InterQual Molecular Diagnostics Criteria nearly doubles the number of tests included and addresses approximately 85-90 percent of the costs in this growing area. Criteria for over 70 pharmacogenomic tests are now available, including BCR-ABL1 (Philly Chromosome) and C-Kit for response to tyrosine kinase inhibitors used to treat certain types of leukemia, and KRAS for response to tyrosine kinase inhibitors for non-small cell lung cancer and advanced pancreatic cancer.
Pharmacogenomic tests, which can predict individual patient response to many specialty pharmaceuticals, help patients get needed, effective care faster. Although they may cost anywhere from a few hundred dollars to over $1,000, these tests have the potential to save as much as $100,000 per year in unnecessary pharmaceutical spending.
Growing at a staggering rate, molecular and genetic test volumes have reached 40 million annual tests in the United States and are expected to double to 80 million by 2012 according to Washington G-2 Reports (2008).Though this fast-growing field holds great promise, it also presents challenges for both health plans and providers as they try to determine test appropriateness and stay educated about medical necessity and test efficacy.

For more information: www.mckesson.com

Related Content

ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA
News | Mammography | November 21, 2018
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Siris Medical Releases PlanMD Decision Support Software
Technology | Treatment Planning | October 24, 2018
Siris Medical Inc. announced the release of its new artificial intelligence (AI) treatment decision-support system for...
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
HealthMyne QIDS Platform Adds Cancer Screening Module
Technology | Clinical Decision Support | August 21, 2018
HealthMyne announced the release of Quantitative Imaging Decision Support (QIDS) 5 featuring a new, automated Cancer...
ACR LI-RADS Steering Committee Releases New Version of CT/MRI LI-RADS
News | Clinical Decision Support | August 13, 2018
August 13, 2018 — The American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) steering commit
Aidoc Receives FDA Clearance for AI Detection of Acute Intracranial Hemorrhage
Technology | Clinical Decision Support | August 08, 2018
Aidoc announced that it was granted U.S. Food and Drug Administration (FDA) clearance for the first product of its...
Videos | Clinical Decision Support | August 03, 2018
Sheila Sferrella, president of Regents Health Resources and Bill Finerfrock, president of Capitol Associates, discuss